

Spondyloarthritis Committee meeting

Date: 27 October 2015

Location: Dee meeting room, NICE Manchester

Minutes: Draft

Committee members present:	
Gary McVeigh (Chair) (GM)	Present for all items
Amanda Isdale (AI)	Present for all items
Louise Warburton (LW)	Present for all items
Tina Hawkins (TH)	Present for all items
Carol McCrum (CM)	Present for all items
Charlotte Davis (CD)	Present for all items
David Chandler (DC)	Present for all items
Jon Packham (JP)	Present for all items
Debbie Cook (DC)	Present for all items
Nicky Bassett-Burr (NBB) – co-opted expert	Present for items up to item 4

In attendance	
Sue Spiers (SS) - <i>Associate Director</i>	Present for all items
Katherine McAllister (KM) - <i>Technical Analyst</i>	Present for all items
Robby Richey (RR) - <i>Technical Analyst</i>	Present for all items
Gabriel Rogers (GR) - <i>Technical Advisor (Health economics)</i>	Present for all items
Hugh McGuire (HM) - <i>Technical Advisor</i>	Present for all items
Rachel Houten (RH) - <i>Health Economist</i>	Present for all items
Louise Shires (LS) - <i>Commissioning Manager</i>	Present for all items
Rupert Franklin (RF) - <i>Commissioning Manager</i>	Present for items up to item 4
Sue Ellerby (SE) – <i>Clinical Advisor</i>	Present for items up to item 4

Apologies:

Nicola Goodson

1. Welcome, minutes of the last meeting, declarations of interest and objectives for the meeting

The Chair welcomed the Committee members and attendees to the ninth guideline development group meeting. He provided a brief overview and objectives of the day highlighting the information that would be discussed.

Apologies were noted, as recorded above and minutes of the last meeting were agreed as an accurate record.

All Committee members were asked to share any new conflicts of interest which have not previously been declared.

No new declarations of interest defined as requiring consideration, for this or future meetings, by the NICE Conflict of Interest policy were made by the committee members present.

2. Update on RQ1 (*signs and symptoms to prompt a healthcare professional to think of spondyloarthritis*) and RQ2 (*risk factors to raise suspicion of spondyloarthritis*)

HM provided an overview of the overarching objective of a range of review questions in supporting the development of recommendations concerning diagnosis and further referral for people with suspected spondyloarthritis.

HM presented the preliminary evidence identified for RQs 1 and 2. The committee considered the evidence and how they would like the evidence presented at a future meeting taking into consideration sensitivity and specificity of the signs and symptoms and risk factors evidenced in the literature.

3. Review question 23 – *When a first-line treatment has failed what is the effectiveness of switching to a different pharmacological intervention or augmenting with a second pharmacological intervention?*

RR presented the available evidence and associated evidence statements. It was noted that there was very limited evidence in this area.

The committee considered the evidence and discussed their own current clinical practice to make recommendations relating to switching/sequencing/augmenting for the pharmacological management of spondyloarthritis.

Additional Agenda Item – Update on RQ18 – *What is the effectiveness of physical aids compared with standard care for managing physical aids?*

KM reminded the committee of their previous considerations for this review question. It was noted that no evidence relating to spondyloarthritis had been identified. The committee reviewed related recommendation(s) from the current rheumatoid arthritis

SA GDG 9 minutes

guideline and using their own clinical experience and expertise made consensus recommendations.

4. RQ33 – *What are the long term complications associated with treatments for spondyloarthritis?*

RR presented the available evidence for this review question. It was noted that the evidence presented was limited and of very low quality. Due to the lack of evidence the committee agreed not to make any recommendations but a research recommendation was agreed for inclusion in the guideline.

5. RQ 7, 8 & 9 – *What is the diagnostic utility of a HLA B27, ESR test and CRP test for investigating suspected spondyloarthritis?*

KM presented an overview on how the evidence for these questions will be presented at a future meeting. It was noted that this evidence will be relevant to recommendations made for RQs 1 and 2 around signs and symptoms / risks.

6. Update on Health Economics

RH presented an overview of health economic analysis in clinical guidelines. A proposed model overview for recognising spondyloarthritis was presented. The committee discussed their preferences for health economic modelling for this guideline.

7. Summary and next steps

There were no additional matters arising. The Chair briefly summarised the discussions from the meeting.

The next meeting will take place on 24 November 2015 in Manchester.